What is Phagenesis?
Phagenesis specializes in the Phagenyx System, a neurostimulation device engineered to enhance swallowing safety and efficiency for patients experiencing post-stroke dysphagia. By employing pharyngeal electrical stimulation, the Phagenyx System aims to restore the brain's natural control over the swallowing reflex, thereby accelerating patient recovery and reducing the duration of hospital stays. The company targets healthcare providers, focusing on improving patient outcomes through evidence-based interventions and extensive clinical research, with the ultimate goal of transforming dysphagia care in clinical settings.
How much funding has Phagenesis raised?
Phagenesis has raised a total of $62.5M across 4 funding rounds:
Series A
$2.3M
Grant
$1.1M
Series B
$17M
Series D
$42M
Series A (2010): $2.3M with participation from Undisclosed
Grant (2012): $1.2M led by Wellcome Trust
Series B (2013): $17M supported by Inventages
Series D (2024): $42M featuring EQT Group, Northern Gritstone, Sectoral Asset Management, and British Patient Capital
Key Investors in Phagenesis
EQT Group
EQT Group is a global investment organization with a thematic approach, targeting high-quality companies in sectors like healthcare and technology, from early-stage ventures to large-cap buyouts.
Northern Gritstone
Northern Gritstone is an investment company dedicated to supporting science and technology businesses, combining strong returns for investors with positive societal impacts.
Sectoral Asset Management
Sectoral Asset Management is an investment advisor specializing in managing equities globally within the healthcare sector, with a strong track record in managing biotech equities.
What's next for Phagenesis?
The recent major enterprise-level funding, including a significant strategic investment, positions Phagenesis for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development, expand clinical adoption of the Phagenyx System, and potentially broaden its therapeutic applications. The company's focus on improving patient outcomes through advanced medical technology, supported by prominent investors in the healthcare and life sciences sectors, suggests a strong trajectory towards becoming a leader in dysphagia management.
See full Phagenesis company page
